Regarding standard biomarkers in all cases of IBC, hormonal status (ER and PR), Ki-67 proliferative index and HER2 are determined, in order to define the prognosis and establish therapeutic possibilities, including hormone therapy, chemotherapy, and anti-HER2 therapy. This evidence concerns the gene MKI67 and inflammatory breast carcinoma.